CD27z CAR-T cells

CD27z CAR-T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target the CD70 antigen, which is frequently overexpressed in glioblastoma and other malignancies. Unlike traditional CAR-T therapies that use a synthetic single-chain variable fragment (scFv) for antigen recognition, the CD27z construct utilizes the natural human CD27 ligand as its extracellular binding domain. This ligand is fused to the CD3ζ (zeta) signaling domain. By employing the natural ligand, the therapy aims to exploit the high affinity of the CD27-CD70 interaction and potentially leverage natural costimulatory signals to enhance T-cell persistence and anti-tumor activity within the immunosuppressive tumor microenvironment. Preclinical studies in orthotopic glioblastoma models and 3D cerebral organoids have demonstrated that this ligand-based approach can offer superior efficacy and tumor infiltration compared to certain scFv-based CD70 CAR designs.

Other names

CD27-zeta CAR-T cellsCD-27-zeta CAR-T cellsCD 27-zeta CAR-T cellsCD27-CD3ζ CAR-T cellsCD70-directed ligand-based CAR-T cellsCD-70-directed ligand-based CAR-T cellsCD 70-directed ligand-based CAR-T cells